Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

I-Mab (IMAB)

12.35   0.36 (3%) 06-26 19:47
Open: 12.31 Pre. Close: 11.99
High: 12.53 Low: 11.71
Volume: 593,332 Market Cap: 1,021(M)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.55 - 12.6 12.6 - 12.65
Low: 11.59 - 11.64 11.64 - 11.69
Close: 12.26 - 12.35 12.35 - 12.43

Technical analysis

as of: 2022-06-24 4:40:50 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 14.63     One year: 17.09
Support: Support1: 9.76    Support2: 8.05
Resistance: Resistance1: 12.52    Resistance2: 14.63
Pivot: 10.38
Moving Average: MA(5): 11.74     MA(20): 9.91
MA(100): 15.78     MA(250): 43.02
MACD: MACD(12,26): 0.1     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 93.2     %D(3): 92.9
RSI: RSI(14): 60
52-week: High: 84.05  Low: 8.05
Average Vol(K): 3-Month: 1,420 (K)  10-Days: 931 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IMAB ] has closed below upper band by 9.3%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 23 Jun 2022
I-Mab Valuation Offers A Biotech Investment Opportunity (NASDAQ:IMAB) - Seeking Alpha

Thu, 23 Jun 2022
2022-06-23 | NDAQ:IMAB | Press Release | I-MAB - Stockhouse

Tue, 21 Jun 2022
Is it Time to Dump I-Mab ADR (IMAB) Stock After it Is Up 32.36% in a Week? - InvestorsObserver

Thu, 16 Jun 2022
I-Mab (NASDAQ:IMAB) Shares Up 4.4% - Defense World

Wed, 15 Jun 2022
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 - BioSpace

Thu, 09 Jun 2022
I-Mab, Ferring team up to develop olamkicept for inflammatory bowel disease - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 78 (M)
% Held by Insiders 3.792e+007 (%)
% Held by Institutions 1 (%)
Shares Short 3,860 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.99e+009
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 274
Return on Equity (ttm) -21
Qtrly Rev. Growth 8.803e+007
Gross Profit (p.s.) -119.15
Sales Per Share -55.68
EBITDA (p.s.) 5.07195e+007
Qtrly Earnings Growth -0.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.23
Price to Cash Flow 0.14

Stock Dividends

Dividend 0
Forward Dividend 4.06e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.